Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial

Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway

(2015) Alessandra Leone et al.   FREE RADICAL BIOLOGY AND MEDICINE

Therapeutic Insights from Genomic Studies of Head and Neck Squamous Cell Carcinomas

(2015) P. S. Hammerman et al.   Cancer Discovery

Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid - short RadioTherapy - rectum 3rd trial)

(2014) Antonio Avallone et al.   BMC CANCER

Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor

(2013) Denise A. Yardley et al.   JOURNAL OF CLINICAL ONCOLOGY

Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome

(2013) Rosa Calemma et al.   Journal of Translational Medicine

Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition

(2013) Barbara Burtness et al.   LANCET ONCOLOGY

Romidepsin for peripheral T-cell lymphoma

(2013) Amit Khot et al.   Expert Review of Hematology

Combination therapy: Histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer

(2012) Himashinie V.K. Diyabalanage et al.   CANCER LETTERS

Targeting ErbB-1 and ErbB-4 in irradiated head and neck cancer: Results of in vitro and in vivo studies

(2012) Itay Barnea et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Cardiac side effects of molecular targeted therapies: Towards a better dialogue between oncologists and cardiologists

(2011) Stephane Ederhy et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: Activation of MET as one mechanism for drug resistance

(2011) Rebekka Krumbach et al.   EUROPEAN JOURNAL OF CANCER

Head neck squamous cell carcinoma c-Met+ cells display cancer stem cell properties and are responsible for cisplatin-resistance and metastasis

(2011) Shuyang Sun et al.   INTERNATIONAL JOURNAL OF CANCER

Histone deacetylase-1 and -2 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival

(2011) Stamatios Theocharis et al.   JOURNAL OF ORAL PATHOLOGY & MEDICINE

Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cells

(2011) Laura Bianchi et al.   PROTEOMICS

Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase

(2010) E Di Gennaro et al.   BRITISH JOURNAL OF CANCER

Molecular and Therapeutic Potential and Toxicity of Valproic Acid

(2010) Sébastien Chateauvieux et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT

(2010) Francesca Bruzzese et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells

(2009) Andrés López-Albaitero et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma

(2009) T. Y. Seiwert et al.   CANCER RESEARCH

Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC

(2009) P. Munster et al.   CLINICAL CANCER RESEARCH

Valproate, in Combination with Pemetrexed and Cisplatin, Provides Additional Efficacy to the Treatment of Malignant Mesothelioma

(2009) F. Vandermeers et al.   CLINICAL CANCER RESEARCH

Evaluation and Management of Cardiac Safety Using the Electrocardiogram in Oncology Clinical Trials: Focus on Cardiac Repolarization (QTc Interval)

(2009) J Morganroth et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

(2009) James A Bonner et al.   LANCET ONCOLOGY

Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis

(2009) F. Bruzzese et al.   MOLECULAR CANCER THERAPEUTICS

Valproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumors

(2008) Alfonso Duenas-Gonzalez et al.   CANCER TREATMENT REVIEWS

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

(2008) Jan B. Vermorken et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epithelial–mesenchymal transition and the invasive potential of tumors

(2008) Nancy Gavert et al.   TRENDS IN MOLECULAR MEDICINE